WO1991016921A1 - Procede et composition destines au traitement du cancer - Google Patents
Procede et composition destines au traitement du cancer Download PDFInfo
- Publication number
- WO1991016921A1 WO1991016921A1 PCT/GB1991/000715 GB9100715W WO9116921A1 WO 1991016921 A1 WO1991016921 A1 WO 1991016921A1 GB 9100715 W GB9100715 W GB 9100715W WO 9116921 A1 WO9116921 A1 WO 9116921A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hormone
- pituitary
- cancer
- pituitary hormone
- tumour cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 37
- 201000011510 cancer Diseases 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims description 14
- 239000000960 hypophysis hormone Substances 0.000 claims abstract description 29
- 239000005556 hormone Substances 0.000 claims abstract description 14
- 229940088597 hormone Drugs 0.000 claims abstract description 14
- 230000001093 anti-cancer Effects 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 230000001817 pituitary effect Effects 0.000 claims abstract description 5
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 4
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 210000004881 tumor cell Anatomy 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 abstract description 9
- 102000018997 Growth Hormone Human genes 0.000 abstract description 8
- 108010051696 Growth Hormone Proteins 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 17
- 210000000987 immune system Anatomy 0.000 description 5
- 102000006877 Pituitary Hormones Human genes 0.000 description 4
- 108010047386 Pituitary Hormones Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- -1 for example Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000001592 luteinising effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Definitions
- This invention relates to a method and composition for the treatment of cancer.
- lymphocytes i.e. cell mediated immunity
- lymphocytes from a patient with a malignant lung tumour can kill pulmonary tumour cells from other patients, but not tumour cells from other tissues. This target specificity could explain some of the original conflicting data on the ability of lymphocytes
- the present invention is based upon the appreciation that stimulation of the immune system by pitutary hormones has utility in the prevention and treatment of cancer.
- a method of treating or preventing cancer in a subject which comprises administering a pituitary hormone.
- the invention further provides the use of a pituitary hormone in the manufacture of a pharmaceutical composition for producing an anti-cancer effect.
- the pituitary hormone is a pituitary glycoprotein hormone, most preferably pituitary growth hormone (HGH) .
- HGH pituitary growth hormone
- Other examples of pituitary hormones include luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone and prolactin.
- Pituitary growth hormone used in accordance with the invention may be characterised in terms of biological activity.
- pituitary growth hormone may be defined as a polypeptide capable of stimulating long bone growth and releasing somatomedin. Such activity may be detected by the methods described in Marx et al. (19* ⁇ 2), Endocrinology, 30, 1. and Greenspan et al. (19* ⁇ 9) . Endocrinology, 45, -455-
- pituitary growth hormone may be defined in terms of its antigenic reaction with
- the anti-cancer effect obtainable in accordance with the invention may be used in the' treatment of cancer itself and also in the prevention of cancer and in the treatment of pre-cancerous conditions, including benign tumours.
- pituitary hormones in accordance with the invention act by exerting an immunostimulant effect, which enabled the body's immune defence mechanisms to reject cancer cells.
- the pituitary glycoprotein hormone may be administered by any convenient means.
- it may be administered orally or parenterally.
- Parenteral modes of administration include administration by injection intravenously, intramuscularly, subcutaneously, intrathecally or into a body cavity, e.g. intraperitoneally or intrapleurally.
- hormone is administered orally for systemic administration, in order to avoid inactivation in the stomach, it is
- SUBSTITUTESHEET preferably administered in the form of an enteric-coated tablet or pill, or in the form of a capsule resistant to degradation in the stomach.
- rectal administration in the form of a suppository, vaginally as a pessary, in the form of an aerosol as in a nasal spray or as eye drops.
- the hormone may be administered in conjunction with an innoculation regime designed to induce the formation of antibodies against cancer cells.
- an innoculation regime may involve injection of inactivated (killed) cancer cells or of antigens derived from cancer cells.
- the pituitary hormone may be administered prior to, simultaneously with or subsequent to the administration of the inactivated (killed) cancer cells or antigen.
- the hormone and inactivated (killed) cancer cells or antigen comprise a single composition adapted for parenteral administration.
- the pharmaceutical preparations according to the invention thus may comprise a single composition containing both the antigen or inactivated (killed) cancer cells and the pituitary hormone or these two components may be present in the form of a kit comprising separate aliquots thereof.
- the pituitary hormone is advantageously administered in a form which encourages localised retention.
- Pharmaceutical conditions embodying such forms (whether or not they additionally comprise one or more of the aforementioned antigens or inactivated (killed) cancer cells) form a further aspect of the invention.
- an injectable pharmaceutical composition for use in conjunction with an antigenic component of an anti-cancer vaccine, said pharmaceutical composition comprising a pituitary hormone and a pharmaceutically acceptable carrier, said carrier (or an optional additional component of the composition) being selected so as to promote localised retention of the pituitary hormone at or adjacent to the injection sites.
- said composition comprises an adjuvant such as, for example, aluminium hydroxide.
- a suitable dose of the of the pituitary hormone is dependent on the mode of application, and the identity of the hormone.
- Pituitary hormone may be used in accordance with the present invention in combination therapies together with other therapeutic agents having an anticancer activity.
- the following regimes illustrates the invention:
- Patients with an inherited predisposition to cancers such as xeroderma pigmentosum and some lymphomas may be treated by injecting HGH into the lesions or removing some of the tumour and reinjecting the tumour along with HGH.
- Patients who have had recent surgery for say example breast cancer, may be treated with HGH as part of their follow-up chemotherapy and their survival and regression rates compared to a control group.
- pituitary hormones via the cell-mediated immune response (rather than by the humoral or antibody response).
- a mode of administration of pituitary hormones which maximises such a response is preferred, i.e. one in which the pituitary hormone is administered in a form which encourages localised retention of the hormone and/or one or more of the aforementioned antigens or inactivated (killed) cancer cells inactivated (killed) cancer cells after injection.
- Such forms include injectable compositions which include known adjuvants such as, for example, aluminium hydroxide.
- compositions may be produced in accordance with the invention comprising both the pituitary hormone and the antigen in a single composition.
- compositions produced in accordance with the invention may comprise conventional pharmaceutically acceptable diluents or carriers.
- typical injectable solutions will comprise sterile pyrogen-free media, e.g. normal saline and optionally include buffering agents, stabilising agents and preservatives.
- conventional enteric coatings may be used.
- Tablets and pills may include conventional excipients such as, for example, lactose, starch and magnesium stearate while suppositories will include excipients such as waxes and glycerol.
- compositions according to the invention are topical compositions for treating cancer .
- Such compositions may comprise a pituitary hormone and an excipient adapted for topical application.
- Such compositions may for example be in the form of creams, ointments, lotions, solutions or gels.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention se rapporte à un procédé de production d'un effet anticancéreux, qui comprend l'administration d'une hormone pituitaire, en particulier d'une hormone pituitaire de glycoprotéine telle qu'une hormone de croissance pituitaire. De plus, l'invention se rapporte à l'utilisation d'une hormone pituitaire dans la fabrication d'une composition pharmaceutique s'utilisant dans le traitement ou la prévention du cancer chez un patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9010058.7 | 1990-05-04 | ||
| GB909010058A GB9010058D0 (en) | 1990-05-04 | 1990-05-04 | Method and composition for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991016921A1 true WO1991016921A1 (fr) | 1991-11-14 |
Family
ID=10675480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1991/000715 WO1991016921A1 (fr) | 1990-05-04 | 1991-05-03 | Procede et composition destines au traitement du cancer |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU7770991A (fr) |
| GB (1) | GB9010058D0 (fr) |
| WO (1) | WO1991016921A1 (fr) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993000109A1 (fr) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance |
| WO1996004008A1 (fr) * | 1994-08-05 | 1996-02-15 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Traitement du cancer par la gonadotrophine chorionique humaine |
| WO1997014428A1 (fr) * | 1995-10-16 | 1997-04-24 | Applied Research Systems | Utilisation de gonadotrophine chorionique humaine dans le traitement du sarcome de kaposi |
| WO2001024822A2 (fr) * | 1999-10-01 | 2001-04-12 | Cistem Biotechnologies Gmbh | Composition pharmaceutique comprenant un antigene |
| US6319504B1 (en) | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
| US6583109B1 (en) | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
| WO2007009383A1 (fr) * | 2005-07-19 | 2007-01-25 | Genescience Pharmaceuticals Co., Ltd. | Suppositoire rectal de proteine et son procede de preparation et son utilisation |
| US7994278B1 (en) | 1999-08-06 | 2011-08-09 | Nobel Biosciences Llc | Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986004241A1 (fr) * | 1985-01-18 | 1986-07-31 | John Mcmichael | Procedes et compositions immunotherapeutiques utilisant des antigenes caracteristiques de neoplasmes de nature maligne |
| WO1987003487A1 (fr) * | 1985-12-09 | 1987-06-18 | John Mcmichael | Procedes et materiaux pour l'allegement de symptomes de la douleur associes a une neoplasie maligne |
| WO1990002559A1 (fr) * | 1988-09-15 | 1990-03-22 | Public Health Laboratory Service Board | Composition pharmaceutique permettant de provoquer un effet immunostimulant |
-
1990
- 1990-05-04 GB GB909010058A patent/GB9010058D0/en active Pending
-
1991
- 1991-05-03 AU AU77709/91A patent/AU7770991A/en not_active Abandoned
- 1991-05-03 WO PCT/GB1991/000715 patent/WO1991016921A1/fr unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986004241A1 (fr) * | 1985-01-18 | 1986-07-31 | John Mcmichael | Procedes et compositions immunotherapeutiques utilisant des antigenes caracteristiques de neoplasmes de nature maligne |
| WO1987003487A1 (fr) * | 1985-12-09 | 1987-06-18 | John Mcmichael | Procedes et materiaux pour l'allegement de symptomes de la douleur associes a une neoplasie maligne |
| WO1990002559A1 (fr) * | 1988-09-15 | 1990-03-22 | Public Health Laboratory Service Board | Composition pharmaceutique permettant de provoquer un effet immunostimulant |
Non-Patent Citations (1)
| Title |
|---|
| Chemical Abstracts, volume 82, no. 1 6th January 1975, (Columbus, Ohio, US) W. Neish: "Growth hormone.. Effect on Rd/3 rat sarcoma growth", see page 53 * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993000109A1 (fr) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance |
| WO1996004008A1 (fr) * | 1994-08-05 | 1996-02-15 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Traitement du cancer par la gonadotrophine chorionique humaine |
| US5677275A (en) * | 1994-08-05 | 1997-10-14 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of cancer with human chorionic gonadotropin |
| US5877148A (en) * | 1994-08-05 | 1999-03-02 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of cancer with human chorionic gonadotropin |
| WO1997014428A1 (fr) * | 1995-10-16 | 1997-04-24 | Applied Research Systems | Utilisation de gonadotrophine chorionique humaine dans le traitement du sarcome de kaposi |
| US6699656B2 (en) | 1996-06-24 | 2004-03-02 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
| US6319504B1 (en) | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
| US6583109B1 (en) | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
| US6620416B1 (en) | 1997-06-24 | 2003-09-16 | University Of Maryland Biotechnology Institute | Method for treating HIV |
| US6699834B1 (en) | 1997-06-24 | 2004-03-02 | University Of Maryland Biotechnology Institute | Method for treating cancer |
| US6805882B1 (en) | 1997-06-24 | 2004-10-19 | University Of Maryland Biotechnology Institute | Therapeutic fractions of sources of HCG |
| US7994278B1 (en) | 1999-08-06 | 2011-08-09 | Nobel Biosciences Llc | Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) |
| US9175077B2 (en) | 1999-08-06 | 2015-11-03 | Nobel Biosciences Llc | Nucleic acids encoding biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) |
| WO2001024822A3 (fr) * | 1999-10-01 | 2001-12-20 | Cistem Biotechnologies Gmbh | Composition pharmaceutique comprenant un antigene |
| WO2001024822A2 (fr) * | 1999-10-01 | 2001-04-12 | Cistem Biotechnologies Gmbh | Composition pharmaceutique comprenant un antigene |
| US8277815B2 (en) | 1999-10-01 | 2012-10-02 | Intercell Ag | Pharmaceutical composition comprising an antigen |
| WO2007009383A1 (fr) * | 2005-07-19 | 2007-01-25 | Genescience Pharmaceuticals Co., Ltd. | Suppositoire rectal de proteine et son procede de preparation et son utilisation |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9010058D0 (en) | 1990-06-27 |
| AU7770991A (en) | 1991-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rees et al. | Increase in incidence of childhood empyema in West Midlands, UK | |
| EP0249629B1 (fr) | Procedes et materiaux pour l'allegement de symptomes de la douleur associes a une neoplasie maligne | |
| CA1336398C (fr) | Methode pour reduire les effets secondaires du traitement anticancereux | |
| WO1991016921A1 (fr) | Procede et composition destines au traitement du cancer | |
| NZ555571A (en) | Alpha thymosin peptides as cancer vaccine adjuvants | |
| US5061488A (en) | Flavone-8-acetic acid and interleukin-2 for cancer therapy | |
| US5096707A (en) | Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers | |
| Durrant et al. | Cancer vaccines entering Phase III clinical trials | |
| Yefenof et al. | Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K | |
| US20060159658A1 (en) | Methods of treating disease with glycosylated interferon | |
| JP2001508764A (ja) | 免疫原性ｔｌｐ組成物 | |
| CN110151987B (zh) | 对称IgG及其组合物在制备治疗及预防肿瘤的药物中的用途 | |
| CN111569046A (zh) | 多肽在制备治疗胰腺炎药物中的用途及含有其的药物 | |
| SU1706624A1 (ru) | Способ лечени опиумно-морфинных наркоманий | |
| Martin | The necessity for combined modalities in cancer therapy | |
| JPS6238329B1 (fr) | ||
| Del Giacco et al. | Combination Chemotherapy and Cytokines in the Treatment of Advanced Primary Lung Cancer: Controlled Clinical Trial Three Year Results | |
| CN111714620A (zh) | Il-12在术后抗肿瘤方面的应用 | |
| RU2003330C1 (ru) | Способ лечени рака молочной железы | |
| Astedt et al. | Cancer, FDP, and radiotherapy. | |
| RU2105567C1 (ru) | Способ лечения злокачественных опухолей | |
| Cheng et al. | A preliminary study of intralesional, intralymph node, intravenous and intraperitoneal Corynebacterium parvum treatments in patients with advanced cancer | |
| Roberts | Immunotherapy in the treatment of cancer | |
| Bartal et al. | The effect of methanol extraction residue of BCG on the cellular immune response in patients with malignant melanoma | |
| Kim et al. | Interleukin-2 and alpha interferon therapy of advanced pulmonary metastases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |